Cure8 news brief
If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on biomarkers that could one day guide patient selection.
Patients with ulcerative colitis or Crohn’s disease who track investigational therapies; clinicians and researchers following emerging biologic/small-molecule programs and biomarker-driven trial designs; investors in biotech developing IBD therapies.
Palisade’s update is primarily a corporate financial and program-status report: it confirms regulatory clearance to begin a Phase 2 trial in ulcerative colitis and describes planned next steps for a Phase 2 Crohn’s program. Timelines given are company targets (enrollment H2 2026; UC primary readout H2 2027; CD readout early 2028).
The note mentions a completed Phase 1 (106 subjects) with favorable safety/PK/PD signals and exploratory findings, but does not provide peer-reviewed efficacy data or detailed results. The company is advancing biomarker-driven patient selection and work toward companion diagnostics, which may affect future trial design and eventual clinical use.
Source is a company financial/SEC filing summary distributed via a business news platform. The article summarizes company-reported milestones and projections rather than peer-reviewed clinical data.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
